综述:靶向过氧化物酶体增殖物激活受体治疗原发性胆汁性胆管炎
本综述通过靶向PubMed检索和手动筛选文献,探讨PPAR各亚型(α、δ、γ)在原发性胆汁性胆管炎(PBC)中的相关通路及PPAR激动剂的结构、生化、临床疗效与安全性特征。PPAR-α和PPAR-δ激动可改善胆汁淤积,不同亚型安全性特征各异,选择性PPAR-δ激动剂seladelpar对瘙痒有统计学显著改善。
要点
- PPAR-α和PPAR-δ激动通过减少胆汁酸合成和炎症改善胆汁淤积。
- PPAR-α激动剂(非标签贝特类、elafibranor)有潜在抗瘙痒作用,seladelpar对瘙痒有统计学显著改善。
- PPAR-α激动与肝脏和肌肉信号相关,PPAR-γ激动与液体潴留/体重增加相关。
核心结论
- PPAR激动剂的亚型选择性影响其疗效和安全性特征,未来需研究亚型特异性机制及症状缓解和药物相关毒性。
研究设计与样本
- 综述通过靶向PubMed检索和手动参考文献筛选,纳入PPAR激动治疗PBC的临床前研究和临床文献。
主要发现
- PPAR-α和PPAR-δ激动通过减少胆汁酸合成和炎症改善胆汁淤积;PPAR-α激动还增强胆汁酸解毒和转运。
- PPAR-δ激动通过减少致痒信号改善胆汁淤积性瘙痒。
- 所有用于PBC的PPAR激动剂均降低碱性磷酸酶水平,但对瘙痒影响不同;PPAR-α predominant激动剂(非标签贝特类、elafibranor)有潜在抗瘙痒效应,选择性PPAR-δ激动剂seladelpar对瘙痒有统计学显著改善。
- 疲劳可能为多因素,由中枢神经系统效应和睡眠障碍介导,PPAR-α和PPAR-δ药物可能获益。
关键数值与推荐
- PPAR-α激动与肝脏和肌肉信号相关;PPAR-γ激动与液体潴留/体重增加相关。
- PPAR-α predominant激动剂(非标签贝特类、elafibranor)有潜在抗瘙痒效应;选择性PPAR-δ激动剂seladelpar对瘙痒有统计学显著改善。
临床怎么用
- PPAR激动剂作为PBC二线选择,需根据亚型选择性权衡疗效(如碱性磷酸酶降低、瘙痒改善)与安全性(肝脏/肌肉信号、液体潴留/体重增加)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primary biliary cholangitis (PBC) is a chronic, immune-mediated liver disease characterised by cholestasis, progressive fibrosis and symptoms of pruritus and fatigue. Ursodeoxycholic acid (UDCA) is first-line therapy; however, many patients respond inadequately or are intolerant. Peroxisome proliferator-activated receptor (PPAR) agonists have emerged as second-line options. AIMS: This review examines PPAR isoform (PPAR-α, PPAR-δ and PPAR-γ) mediated pathways relevant to PBC, and structural, biochemical and clinical efficacy and safety features of PPAR agonists for PBC. METHODS: Preclinical studies on therapeutic PPAR agonism and clinical literature on PPAR agonists in PBC were identified through targeted PubMed searches and manual reference screening. RESULTS: PPAR-α and PPAR-δ agonism improve cholestasis by reducing bile acid synthesis and inflammation. PPAR-α agonism also enhances bile acid detoxification and transport, while PPAR-δ agonism improves cholestatic pruritus by reducing pruritogenic signals. Individual PPAR isoforms are also associated with different safety profiles, with PPAR-α agonism linked to hepatic and muscle signals, and PPAR-γ agonism associated with fluid retention/weight gain. PPAR agonists differ in isoform selectivity. Although all agonists used in PBC reduce alkaline phosphatase levels, their impact on pruritus varies; PPAR-α predominant agonists (off-label fibrates, elafibranor) have a potential anti-pruritic effect, while selective PPAR-δ agonist, seladelpar, has demonstrated statistically significant improvements in pruritus. Fatigue is likely multifactorial, mediated through central nervous system effects and sleep disturbance; PPAR-α and PPAR-δ agents offer possible benefit. CONCLUSIONS: Isoform selectivity contributes to the efficacy and safety profiles of PPAR agonists. Future research should investigate isoform-specific mechanisms, particularly regarding symptom relief and agent- and class-related toxicities.
引用
- Schattenberg JM, Banales JM, Hirschfield G, et al. Review Article: Targeting Peroxisome Proliferator-Activated Receptors in Primary Biliary Cholangitis. Aliment Pharmacol Ther. 2026. PMID: 41906662. doi:10.1111/apt.70598
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。